NCT04892953View on ClinicalTrials.gov

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Stage III Lung Cancer AJCC v8Stage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Cancer AJCC v8Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Cancer AJCC v8Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IIIC Lung Cancer AJCC v8
Interventions
DRUG

Carboplatin

Given IV

BIOLOGICAL

Durvalumab

Given IV

DRUG

Gemcitabine

Given IV

PROCEDURE

Local Consolidation Therapy

Undergo LCT

DRUG

Nab-paclitaxel

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Pemetrexed

Given IV

OTHER

Quality-of-Life Assessment

Complete questionnaire

OTHER

Questionnaire Administration

Complete questionnaire

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER